Top Markets
#1 Purr Purr +61.35%
#2 Smilek to the Bank Smilek to the Bank +50.56%
#3 Pons Pons +46.97%
#4 Kinetiq Kinetiq +32.46%
#5 Non-Playable Coin Non-Playable Coin +25.94%
#6 ApeX ApeX +23.78%
#7 Morpho Morpho +19.65%
#8 OriginTrail OriginTrail +19.49%
#9 Pudgy Penguins Pudgy Penguins +19.22%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +18.90%
Coin of the day
Purr Purr
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Coya Therapeutics, Inc. Coya Therapeutics, Inc.

Coya Therapeutics, Inc.

COYA
Clasificación en acciones #21166
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on... Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
Precio por acción
$4.83
Última sincronización: 2026-08-21
Capitalización bursátil
$113.30M
Cambio (1 día)
-0.62%
Cambio (1 año)
-29.59%
País
US
Comercio Coya Therapeutics, Inc. (COYA)

Categoría

Healthcare
Historial del precio de la acción de Coya Therapeutics, Inc. (COYA)
Precio más alto de cierre: $4.77 el 2026-08-01

Precio más bajo de cierre: $4.65 el 2022-12-01
Historial del precio de la acción de Coya Therapeutics, Inc. desde 2022 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2026 (TTM) -10.79%
2025 0.58%
2024 -19.02%
2023 53.38%
2022 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $547.71 38.62%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.04K 58.06%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $145.75 437.43%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $118.70 -15.60%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $770.19 8.98%
CH